Article Text

Download PDFPDF

2022-RA-439-ESGO Up-next (ENGOT-Ov71-NSGO-CTU/GOG-3049): a study of upitifamab rilsodotin (UpRi), a napi2b-directed antibody drug conjugate (ADC) in platinum-sensitive recurrent ovarian cancer
  1. Mansoor Raza Mirza1,
  2. David M O’Malley2,
  3. Philipp Harter3,
  4. Thomas J Herzog4,
  5. Antonio Gonzalez-Martin5,
  6. Caroline Rogalski6,
  7. Robert A Burger6 and
  8. Debra L Richardson7
  1. 1Rigshospitalet – University Hospital Copenhagen, Copenhagen, Denmark
  2. 2Ohio State University, Columbus, OH
  3. 3Kliniken Essen Mitte, Essen, Germany
  4. 4University of Cincinnati, Cincinnati, OH
  5. 5Clínica Universidad de Navarra, Madrid, Spain
  6. 6Mersana Therapeutics, Cambridge, MA
  7. 7Stephenson Cancer Centre-University of Oklahoma, Oklahoma City, OK


Introduction/Background UpRi is a first-in-class NaPi2b-targeting ADC with a novel scaffold-linker-payload that enables high drug-to-antibody ratio and controlled bystander effect. NaPi2b is a sodium-dependent phosphate transporter protein broadly expressed in high-grade serous ovarian cancer (HGSOC) with limited expression in healthy tissues. It’s estimated that about two-thirds of HGSOC patients are NaPi2b-high. Studies are being conducted to evaluate UpRi safety and efficacy in platinum-resistant ovarian cancer (PROC), but there remains an unmet need in the maintenance setting for patients with platinum-sensitive, recurrent ovarian cancer (PSOC), particularly in patients who received standard of care treatment (platinum-based chemotherapy) and are at high-risk of early relapse.

Methodology UP-NEXT is a Ph3 study evaluating UpRi monotherapy as post-platinum maintenance therapy in recurrent PSOC, enrolling patients with NaPi2b-high tumors (defined as TPS ≥75). Patients must have received 2–4 prior lines of platinum containing chemotherapy, achieved a partial or complete response in their penultimate platinum regimen, and progressed >6 mo after completion of the last dose of platinum. Patients may be enrolled if their best response to the last line of treatment is no evidence of disease, complete or partial response, or stable disease. If patients have a known BRCA mutation, prior PARPi treatment is required. Patients who received bevacizumab in combination with their last platinum containing regimen are excluded. Patients are randomized 2:1 to UpRi or placebo, given IV Q4W. The primary endpoint is PFS assessed by BICR, with key secondary endpoint of OS. UP-NEXT is conducted in collaboration with ENGOT(Ov71-NSGO-CTU) and GOG(3049). ~350 patients will be enrolled globally. NCT05329545

Results N/A – trial in progress

Conclusion N/A – trial in progress

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.